keyword
https://read.qxmd.com/read/26238298/duloxetine-in-treating-generalized-anxiety-disorder-in-adults-a-meta-analysis-of-published-randomized-double-blind-placebo-controlled-trials
#21
JOURNAL ARTICLE
Yingli Zhang, Guoping Huang, Shichang Yang, Wei Liang, Lei Zhang, Changhong Wang
INTRODUCTION: We carried out a meta-analysis of published randomized, double-blind, placebo-controlled trails to assess the efficacy and tolerability of duloxetine in treating generalized anxiety disorder (GAD). METHODS: A literature search was conducted using PubMed, ISI Web of Science, Medline, Cochrane Central Register of Controlled Trials databases until October 2014. The search terms used were "anxiety or anxious or generalized anxiety disorder" and "duloxetine or Cymbalta...
September 2016: Asia-Pacific Psychiatry: Official Journal of the Pacific Rim College of Psychiatrists
https://read.qxmd.com/read/25768099/interventions-to-treat-premature-ejaculation-a-systematic-review-short-report
#22
REVIEW
Katy Cooper, Marrissa Martyn-St James, Eva Kaltenthaler, Kath Dickinson, Anna Cantrell
BACKGROUND: Premature ejaculation (PE) is commonly defined as ejaculation with minimal sexual stimulation before, on or shortly after penetration and before the person wishes it. PE can be either lifelong and present since first sexual experiences (primary), or acquired (secondary), beginning later (Godpodinoff ML. Premature ejaculation: clinical subgroups and etiology. J Sex Marital Ther 1989;15:130-4). Treatments include behavioural and pharmacological interventions. OBJECTIVE: To systematically review evidence for clinical effectiveness of behavioural, topical and systemic treatments for PE...
March 2015: Health Technology Assessment: HTA
https://read.qxmd.com/read/24914505/can-chronic-pain-patients-be-adequately-treated-using-generic-pain-medications-to-the-exclusion-of-brand-name-ones
#23
REVIEW
Kenneth D Candido, Joseph Chiweshe, Utchariya Anantamongkol, Nebojsa Nick Knezevic
According to the Food and Drug Administration (FDA) reports, approximately 8 in 10 prescriptions filled in the United States are for generic medications, with an expectation that this number will increase over the next few years. The impetus for this emphasis on generics is the cost disparity between them and brand-name products. The use of FDA-approved generic drugs saved 158 billion dollars in 2010 alone. In the current health care climate, there is continually increasing pressure for prescribers to write for generic alternative medications, occasionally at the expense of best clinical practices...
March 2016: American Journal of Therapeutics
https://read.qxmd.com/read/24488184/how-does-direct-to-consumer-advertising-affect-the-stigma-of-mental-illness
#24
RANDOMIZED CONTROLLED TRIAL
Patrick W Corrigan, Kristin A Kosyluk, J Konadu Fokuo, Jin Hee Park
Stigma interferes with life goals of people with mental illness. Direct-to-consumer advertising (DTCA) may impact stigmatizing attitudes. The purpose of this study is to examine the effects of psychiatric medication DTCA on the stigmatizing and affirming attitudes of the general population versus individuals self-identified with mental illness. Participants (n = 272) were randomly assigned to watch a DTCA about Cymbalta, an antidepressant, embedded in two other advertisements for non-pharmaceutical products...
October 2014: Community Mental Health Journal
https://read.qxmd.com/read/24378318/the-prevalence-of-duloxetine-in-medico-legal-death-investigations-in-victoria-australia-2009-2012
#25
JOURNAL ARTICLE
Jennifer L Pilgrim, Dimitri Gerostamoulos, Olaf H Drummer
The drug duloxetine (Cymbalta(®)) is a newer antidepressant which has been available in Australia since 2008. Duloxetine is a serotonin and noradrenaline reuptake inhibitor (SNRI), which is associated with adverse effects in the first 6 weeks of therapy, including tachycardia and worsening symptoms in people with advanced heart failure. It is also associated with serotonin toxicity in combination with certain drugs. Few reports have been published in the toxicology literature regarding duloxetine and its prevalence in coroners' cases...
January 2014: Forensic Science International
https://read.qxmd.com/read/24314785/treatment-of-hidradenitis-supprurativa-associated-pain-with-nonsteroidal-anti-inflammatory-drugs-acetaminophen-celecoxib-gabapentin-pegabalin-duloxetine-and-venlafaxine
#26
REVIEW
Noah Scheinfeld
Hidradenitis Supprurativa is a painful dermatological condition. Although the pain of HS has unique aspects, the pain of HS pain shares common elements with essential pain, fibromyalgia, and pure neuropathic pain syndromes. Futhermore, depression plays an important role in the pain of HS. This paper reviews the potential for use of nonsteroidal anti-inflammatory drug (NSAIDS), acetaminophen, celecoxib, gabpentin, pregabalin, and the serotonin and norepinephrine reuptake inhibitors (SNRIs), duloxetine and venlafaxine, for treating HS related pain...
November 15, 2013: Dermatology Online Journal
https://read.qxmd.com/read/23599035/pharmacokinetic-analysis-of-two-different-doses-of-duloxetine-following-oral-administration-in-dogs
#27
JOURNAL ARTICLE
I-H Baek, B-Y Lee, W Kang, K-I Kwon
BACKGROUND: Duloxetine is a potent and balanced dual inhibitor of serotonin and norepinephrine reuptake that is being investigated for the treatment of depression and urinary incontinence. The purpose of this study was to investigate the pharmacokinetic properties of duloxetine in 20 beagle dogs following a single oral administration of a 30- or 60-mg enteric-coated pellet in a capsule (Cymbalta). METHOD: Following the administration of 30 or 60 mg of Cymbalta to 20 beagle dogs, the plasma concentration of duloxetine was measured using LC-MS/MS...
August 2013: Drug Research
https://read.qxmd.com/read/23539870/-cymbalta-also-controls-the-pain-of-knee-arthrosis
#28
Guy Sabourin
No abstract text is available yet for this article.
March 2013: Perspective Infirmière: Revue Officielle de L'Ordre des Infirmières et Infirmiers du Québec
https://read.qxmd.com/read/23469485/-is-there-a-place-for-the-physician-s-hopelesness-in-the-treatment-of-depression
#29
JOURNAL ARTICLE
W Pitchot
In the treatment of depression, the main objective is to reach complete remission. Unfortunately, this objective remains difficult in clinical practice. In fact, complete remission is frequently considered as an unrealistic objective. It is clear that recovering from major depression is a complicated objective, but it is realistic. In the present paper, we describe the case of a patient suffering from treatment-resistant chronic depression that remitted with a combination of duloxetine (Cymbalta) and aripiprazole (Abilify)...
February 2013: Revue Médicale de Liège
https://read.qxmd.com/read/23239363/duloxetine-a-review-of-its-use-in-the-management-of-major-depressive-disorder-in-older-adults
#30
REVIEW
Sohita Dhillon
Duloxetine (Cymbalta(®)) is a selective serotonin norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD). This article reviews the therapeutic efficacy and tolerability of duloxetine in older adults with MDD and summarizes its pharmacological properties. Treatment with duloxetine significantly improved several measures of cognition, depression, anxiety, pain and health-related quality-of-life (HR-QOL) in older adults with MDD in two 8-week, double-blind, placebo-controlled trials...
January 2013: Drugs & Aging
https://read.qxmd.com/read/22688722/intensive-monitoring-of-duloxetine-results-of-a-web-based-intensive-monitoring-study
#31
JOURNAL ARTICLE
Linda Härmark, Eugène van Puijenbroek, Kees van Grootheest
PURPOSE: Duloxetine (Cymbalta(®)) is a serotonin (5-HT) and norepinephrine (NE) re-uptake inhibitor indicated for the treatment of depression, diabetic peripheral neuropathic pain and general anxiety disorder. The aim of this study is to gain insight in the user and safety profile of duloxetine in daily practice, reported by patients via a web-based intensive monitoring system during their first 6 months of use. METHODS: First-time users of duloxetine were identified through the first dispensing signal in the pharmacy...
February 2013: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/22351288/acute-massive-pulmonary-thromboembolism-due-to-acute-intoxication-by-duloxetine-a-case-report
#32
JOURNAL ARTICLE
Francesco Mari, Barbara Gualco, Regina Rensi, Elisabetta Bertol
Duloxetine (Cymbalta) is a potent serotonin norepinephrine reuptake inhibitor used for the management of major depression and pain associated with diabetic peripheral neuropathy. Cymbalta delayed-release capsules contain Duloxetine HCl equivalent to 20, 30, 60 mg of Duloxetine. The ingestion of high quantities of Duloxetine may have serious outcomes such as venous thrombosis, causing cardiac respiratory arrest. The Authors outline a case report of an elderly woman, suffering from depression, found dead in her apartment...
September 2012: Cardiovascular Toxicology
https://read.qxmd.com/read/21463069/examining-the-use-of-tramadol-hydrochloride-as-an-antidepressant
#33
JOURNAL ARTICLE
Justin Barber
Tramadol (Ultram, Ultracet) is a centrally acting synthetic opioid with analgesic efficacy comparable to codeine. Antinociception is attributed to low but effective affinity for the mu-opioid receptor (μ), as well as reuptake inhibition of the monoamines norepinephrine (NE) and serotonin (5HT). Dual action antidepressants mirtazapine (Remeron), duloxetine (Cymbalta), and most notably venlafaxine (Effexor), which tramadol is closely related to in structure, also inhibit NE and 5HT reuptake. These medications are proven effective antidepressants and this shared monoaminergic action resulted in the research of tramadol as a potential treatment for depression...
April 2011: Experimental and Clinical Psychopharmacology
https://read.qxmd.com/read/20570459/artifactual-formylation-of-the-secondary-amine-of-duloxetine-hydrochloride-by-acetonitrile-in-the-presence-of-titanium-dioxide-implications-for-hplc-method-development
#34
JOURNAL ARTICLE
M J Skibic, L A King, M Khan, P J Fox, B E Winger, S W Baertschi
Duloxetine hydrochloride, a secondary amine containing pharmaceutical, currently marketed as Cymbalta, is shown to undergo N-formylation as an artifact of sample preparation prior to HPLC analysis for impurities. The reaction was discovered as a result of an investigation into variability in the levels of N-formyl duloxetine observed upon HPLC analysis. The reaction is catalyzed by sonication and/or light in the presence of titanium dioxide and is proposed to occur via a radical-initiated mechanism. The mechanism is supported by controlled sample preparation studies with deuterium-labeled acetonitrile and LC/MS studies that showed incorporation of one deuterium into N-formyl duloxetine...
November 2, 2010: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/20532153/treatment-of-fibromyalgia
#35
JOURNAL ARTICLE
Peter Dussias, Amir H Kalali, Roland M Staud
In this article, we investigate the range of treatments prescribed for fibromyalgia. The data suggest that the majority of those treated, 82 percent, receive only one pharmaceutical. An additional 12 percent of patients were prescribed two products and six percent received three products. Pregabalin (Lyrica(R)) monotherapy was the most commonly prescribed regimen (21% of patients) followed by duloxetine (Cymbalta(R)) monotherapy (20%). From a therapeutic class perspective, fibromyalgia patients received antidepressants (46%), antiepileptics (35%), pain therapies (25%), muscle relaxants (8%), and sleep agents (2%)...
May 2010: Psychiatry
https://read.qxmd.com/read/20436760/use-of-antidepressants-expansion-beyond-depression-and-anxiety
#36
JOURNAL ARTICLE
Elisa F Cascade, Amir H Kalali, Michael E Thase
We investigated antidepressant prescriptions and reasons for use. According to our data, the top 10 molecules represent approximately 95% of total antidepressant prescriptions for both primary care physicians (PCPs) and psychiatrists. The primary difference between PCPs and psychiatrists was the increased use of buproprion and tricyclics/tetracyclics by psychiatrists. The selective serotonin reuptake inhibitors (SSRIs) and other newer antidepressants such as venlafaxine (Effexor) and buproprion (Wellbutrin) are used to treat depression, anxiety, and bipolar disorders...
December 2007: Psychiatry
https://read.qxmd.com/read/19727297/treatment-of-fibromyalgia
#37
JOURNAL ARTICLE
Elisa F Cascade, Amir H Kalali, Nikhil D Nihalani, Thomas L Schwartz
In this article, we investigate the range of treatments prescribed for fibromyalgia. The data suggest that the majority of those treated, 72 percent, receive only one pharmaceutical. An additional 18 percent of patients were prescribed two products and 10% received three products. Pregabalin (Lyrica(R)) monotherapy was the most commonly prescribed regimen (28% of patients) followed by duloxetine (Cymbalta(R)) monotherapy (6%). From a therapeutic class perspective, fibromyalgia patients received pain therapies (42%), antiepileptics (40%), antidepressants (28%), muscle relaxants (14%), and sleep agents (8%)...
March 2008: Psychiatry
https://read.qxmd.com/read/19608694/in-vitro-inhibition-and-induction-of-human-liver-cytochrome-p450-enzymes-by-milnacipran
#38
JOURNAL ARTICLE
Brandy L Paris, Brian W Ogilvie, Julie A Scheinkoenig, Florence Ndikum-Moffor, Remi Gibson, Andrew Parkinson
Milnacipran (Savella) inhibits both norepinephrine and serotonin reuptake and is distinguished by a nearly 3-fold greater potency in inhibiting norepinephrine reuptake in vitro compared with serotonin. We evaluated the ability of milnacipran to inhibit and induce human cytochrome P450 enzymes in vitro. In human liver microsomes, milnacipran did not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, or 2D6 (IC(50) >or= 100 microM); whereas, a comparator with dual reuptake properties [duloxetine (Cymbalta)] inhibited CYP2D6 (IC(50) = 7 microM) and CYP2B6 (IC(50) = 15 microM) with a relatively high potency...
October 2009: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://read.qxmd.com/read/19480470/duloxetine-a-review-of-its-use-in-the-treatment-of-generalized-anxiety-disorder
#39
REVIEW
Natalie J Carter, Paul L McCormack
Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effective with regard to improvement from baseline in assessments of anxiety and functional impairment, and numerous other clinical endpoints. Longer-term duloxetine 60-120 mg once daily also demonstrated efficacy in preventing or delaying relapse in responders among patients with GAD...
2009: CNS Drugs
https://read.qxmd.com/read/19476393/total-residue-analysis-of-swabs-by-ion-mobility-spectrometry
#40
JOURNAL ARTICLE
Mark A Strege
Ion mobility spectrometry (IMS) is a technique attractive for use within the pharmaceutical industry for at-line determination of residues on swabs taken from the surfaces of manufacturing equipment for the purposes of cleaning validation or verification. In this study, the development of a novel IMS method to provide a measurement of total residue present on a swab is described. The technique is based upon quantitation of charged atmospheric gas reactant ion consumption (RIC) within the instrument as a direct measure of the mass of total ionizable residue...
June 1, 2009: Analytical Chemistry
keyword
keyword
1005
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.